化合物PLX647 T1925

Product Introduction
Bioactivity


英文名: PLX647

描述: PLX647 是具有口服活性的、高效的、特异性的FMS 和KIT 双激酶抑制剂，IC50分别为 28 和 16 nM。它 (1 μM) 在 400 个激酶组中显示出对 FMS 和 KIT 有选择性，但 FLT3 和 KDR 除外 (IC50=91 和 130 nM)。

激酶实验: HTS screen: To start an assay, 0.5 μL of 5 mg/mL test compound (about 50 μM final reaction concentration) or DMSO control is aliquoted into each well. Both enzyme and substrate are prepared in UCH reaction buffer (50 mM Tris-HCl [pH 7.6], 0.5 mM EDTA, 5 mM DTT, and 0.5 mg/mL ovalbumin). 25 μL of 0.6 nM UCH-L1 is then added to each well except substrate control wells, followed by plate shaking for 45–60 s on an automatic shaker. The enzyme/compound mixture is incubated at room temperature for 30 min before 25 μL of 200 nM Ub-AMC is added to initiate the enzyme reaction. The reaction mixture (300 pM UCH-L1, 100 nM Ubiquitin-AMC with 2.5 μg test compound) is incubated at room temperature for 30 additional minutes prior to quenching the reaction by the addition of 10 μL 500 mM acetic acid per well. The fluorescence emission intensity is measured on a LJL Analyst using a coumarin filter set (ex = 365 nm, em = 450 nm) and is subtracted by the intrinsic compound fluorescence to reveal the enzyme activity. A DMSO control (0.5 μL of DMSO, 25 μL of UCH-L1, 25 μL of ubiquitin-AMC, 10 μL of acetic acid), enzyme control (25 μL of UCH-L1, 25 μL of buffer, 10 μL of acetic acid), substrate control (25 μL of buffer, 25 μL of ubiquitin-AMC, 10 μL of acetic acid), and inhibitor control (0.5 μL of ubiquitin aldehyde [100 nM stock], 25 μL of UCH-L1, 25 μL of ubiquitin-AMC, 10 μL of acetic acid) are also performed in each assay plate to ensure quality and reproducibility. Potential UCH-L1 inhibitors are selected if the compounds demonstrated greater than 60% inhibition compared to the controls. The UCH-L1 enzymatic reactions are manually repeated twice using the same protocol to confirm the results for the hit compounds from the primary robot-assisted screen.

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 31 mg/mL


关键字: c-Fms | c-Kit | Inhibitor | cells | osteoclast | SCFR | BCR-FMS | CD117 | bone | PLX647 | PLX-647 | differentiation | colony stimulating factor 1 receptor | BCR-KIT | PLX 647 | CSF1R | inhibit | CSF-1 receptor | proliferation | CSF-1R

相关产品: PLX5622 hemifumarate | Sotuletinib dihydrochloride | GW2580 | Vimseltinib | Nampt-IN-1 | CSF1R-IN-2 | c-Fms-IN-14 | c-Fms-IN-9 | c-Fms-IN-6 | Anti-Mouse GM-CSF Antibody (MP1-22E9)

化合物PLX647 T1925信息由TargetMol中国为您提供，如您想了解更多关于化合物PLX647 T1925报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途